The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 59, Issue 8-9, 2003, Pages 615-619

  Oda, Manami ^a   Kotegawa, Tsutomu ^a   Tsutsumi, Kimiko ^a   Ohtani, Yasukiyo ^a   Kuwatani, Keiji ^a   Nakano, Shigeyuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Bromazepam; CYP3A4; Itraconazole

Indexed keywords

BROMAZEPAM; CYTOCHROME P450 3A4; ITRACONAZOLE; SENIRAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; ELECTROENCEPHALOGRAM; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION;

ADULT; ANTI-ANXIETY AGENTS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BROMAZEPAM; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; ITRACONAZOLE; MALE;

EID: 0344303626     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0681-4     Document Type: Article

References (24)

1. Schwartz MA, Postma E, Kolis SJ, Leon AS (1973) Metabolites of bromazepam, a benzodiazepine, in the human, dog, rat, and mouse. J Pharm Sci 62:1776-1779
2. Kaplan SA, Jack ML, Weinfeld RE, Glover W, Weissman L, Cotler S (1976) Biopharmaceutical and clinical pharmacokinetic profile of bromazepam. J Pharmacokinet Biopharm 4:1-16
3. Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI (1987) Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther 41:562-570
4. van Harten J, Holland RL, Wesnes K (1992) Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomized, cross-over study. Eur Neuropsychopharmacol 2:381P
5. Ohtani Y, Kotegawa T, Tsutsumi K, Morimoto T, Hirose Y, Nakano S (2002) Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: an application of electroencephalography as the pharmacodynamic method. J Clin Pharmacol 42:183-191
6. Hargreaves JA, Jezequel S, Houston JB (1994) Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam. Br J Clin Pharmacol 38:175P
7. Collignon P, Hurley B, Mitchell D (1989) Interaction of fluconazole with cyclosporin. Lancet 1:1262P
8. Torregrosa V, de la Torre M, Campistol JM, Oppenheimer F, Ricart MJ, Vilardell J, Andreu J (1992) Interaction of fluconazole with cyclosporin A. Nephron 60:125-126
9. Krüger HU, Schuler U, Zimmermann R, Ehninger G (1989) Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 24:781-786
10. Lazar JD, Wilner KD (1990) Drug interactions with fluconazole. Rev Infect Dis 12:S327-S333
11. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111-180
12. Bailey DG, Malcolm J, Arnold O, Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110
13. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349-356
14. Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485
15. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607
16. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269-273
17. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ (1987) Interaction of cyclosporine and itraconazole. Lancet 2:282
18. Trenk D, Brett W, Jähnchen E, Birnbaum D (1987) Time course of cyclosporine/itraconazole interaction. Lancet 2:1335-1336
19. Neuvonen PJ, Kantola T, Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:332-341
20. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP (1991) Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101:1680-1691
21. Caccia S (1998) Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281-302
22. Preskorn SH (1997) Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 32[Suppl1]:1-21
23. Kyriakopoulos AA, Greenblatt DJ, Shader RI (1978) Clinical pharmacokinetics of lorazepam: a review. J Clin Psychiatry 39:16-23
24. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker S Jr, Speeg KV (1980) Cimetidine spares the glucuronidation of lorazepam and oxazepam. Gastroenterology 79:912-916